Abstract
Drugs may induce hair loss, stimulate hair growth or, more rarely, induce changes in the hair shape and colour. Drug-induced hair loss is usually completely reversible and is, in most cases, a consequence of a toxic effect of the drug on the hair follicle matrix. In rare cases alopecia may be permanent. Depending on type of drug, dosage and patient susceptibility, hair loss presents as telogen effluvium, anagen effluvium or both. Telogen effluvium is also commonly observed after discontinuation of drugs that prolong anagen, such as topical minoxidil and oral contraceptives. Although a large number of drugs have been occasionally reported to produce hair loss, only for a few drugs the relation between drug intake and hair loss has been proven.
Current Drug Safety
Title: Drug-Induced Hair Disorders
Volume: 1 Issue: 3
Author(s): Bianca Maria Piraccini, Matilde Iorizzo, Giulia Rech and Antonella Tosti
Affiliation:
Keywords: Hair loss, alopecia, drugs
Abstract: Drugs may induce hair loss, stimulate hair growth or, more rarely, induce changes in the hair shape and colour. Drug-induced hair loss is usually completely reversible and is, in most cases, a consequence of a toxic effect of the drug on the hair follicle matrix. In rare cases alopecia may be permanent. Depending on type of drug, dosage and patient susceptibility, hair loss presents as telogen effluvium, anagen effluvium or both. Telogen effluvium is also commonly observed after discontinuation of drugs that prolong anagen, such as topical minoxidil and oral contraceptives. Although a large number of drugs have been occasionally reported to produce hair loss, only for a few drugs the relation between drug intake and hair loss has been proven.
Export Options
About this article
Cite this article as:
Maria Piraccini Bianca, Iorizzo Matilde, Rech Giulia and Tosti Antonella, Drug-Induced Hair Disorders, Current Drug Safety 2006; 1 (3) . https://dx.doi.org/10.2174/157488606777934477
DOI https://dx.doi.org/10.2174/157488606777934477 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Imidazole Containing Natural Products as Antimicrobial Agents: A Review
The Natural Products Journal Peripheral Benzodiazepine Receptor (PBR) New Insight in Cell Proliferation and Cell Differentiation Review
Current Clinical Pharmacology Points of Therapeutic Intervention Along the Wnt Signaling Pathway in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry The Role of Anti-LeY Antibody in the Downregulation of MAPKs/COX-2 Pathway in Gastric Cancer
Current Drug Targets Roles of Hypoxia During the Chondrogenic Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Lipid Nanoparticles as a Skin Wound Healing Drug Delivery System: Discoveries and Advances
Current Pharmaceutical Design Topoisomerases and Tubulin Inhibitors: A Promising Combination for Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Heparin Affin Regulatory Peptide: A New Target for Tumour Therapy?
Current Cancer Drug Targets Flavonoids, Breast Cancer Chemopreventive and/or Chemotherapeutic Agents
Current Medicinal Chemistry Regulation of Bcl-2 Family Proteins by Posttranslational Modifications
Current Molecular Medicine Does Religiosity Protect Against Cognitive and Behavioral Decline in Alzheimers Dementia?
Current Alzheimer Research Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design Medicinal Chemistry Insights into Novel HDAC Inhibitors: An Updated Patent Review (2012-2016)
Recent Patents on Anti-Cancer Drug Discovery Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets Immunotherapy of Pancreatic Carcinoma
Reviews on Recent Clinical Trials Modulation of Matrix Metalloproteinases by Plant-derived Products
Current Cancer Drug Targets Fibroblast Growth Factor Receptor Signaling in Cancer Biology and Treatment
Current Signal Transduction Therapy Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy
Current Medicinal Chemistry Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease
Current Alzheimer Research